News | February 12, 2015

Pocket ECG Supports Study by Texas Cardiac Arrhythmia Research Foundation

Study investigating impact of lifestyle modification on ablation outcome in atrial fibrillation

February 12, 2015 — Medi-Lynx Cardiac Monitoring LLC and Medicalgorithmics have announced their participation in a research project investigating the impact of lifestyle modification on ablation outcome in atrial fibrillation (ISOLATE).  Medicalgorithmics’ PocketECG cardiac monitoring system will be used for collecting and analyzing the electrocargiogram (ECG) data in the project.

The research started in August 2014, financed by Texas Cardiac Arrhythmia Research Foundation. It will evaluate the impact of aggressive lifestyle modification, in terms of calorie-controlled diet and supervised exercise, on outcomes of catheter ablation in overweight and obese patients with atrial fibrillation. The hypothesis states that weight loss and management by adoption of a strict diet and exercise regimen improves the chances of freedom from recurrence following catheter ablation.

The PocketECG system recognizes the morphology of each individual heartbeat and allows differentiating between normal and abnormal heartbeats including ventricular ectopy, supraventricular ectopy, aberrated supraventricular beats, artifact, etc. This functionality combined with the capability of streaming the continuous ECG for many weeks provides reliable Heart Rate Variability statistics over an extended monitoring period.  The system also has the ability to calculate detailed arrhythmia statistics for extended monitoring sessions and to identify HRV changes and morphology of each individual QRS complex.

The study’s eligible group is overweight or obese adult patients with a diagnosis of atrial fibrillation undergoing first catheter ablation at least three months after the enrollment. Supervised and monitored exercise will be conducted in St. David's Cardiac Rehabilitation for at least three months before ablation. After ablation, patients will continue an individualized home-exercise program for one year.

For more information: www.medicalgorithmics.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now